The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Machleidt, Anna ^a   Buchholz, Stefan ^a   Diermeier Daucher, Simone ^a   Zeman, Florian ^b   Ortmann, Olaf ^a   Brockhoff, Gero ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Her2 positive breast cancer; Her4 expression; Her4 isoforms; qPCR; Triple negative breast cancer

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84884469101     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-437     Document Type: Article

References (35)

1. Hardy KM, Booth BW, Hendrix MJ, Salomon DS, Strizzi L. ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2010, 15(2):191-199. Review, 10.1007/s10911-010-9172-2, 2889136, 20369376.
2. Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia 2008, 13(2):235-246. 10.1007/s10911-008-9080-x, 3325098, 18437540.
3. Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA, Earp HS. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol 2009, 29(18):4935-4948. 10.1128/MCB.01705-08, 2738276, 19596786.
4. Jones FE. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13(2):247-258. 10.1007/s10911-008-9076-6, 2442669, 18473151.
5. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990, 45(3):457-461. 10.1002/ijc.2910450314, 1968437.
6. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011, 9(1):16-32. Review, 10.1038/nrclinonc.2011.177, 22124364.
7. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in breast cancer. Clin Cancer Res 2009, 15(24):7479-7491. 10.1158/1078-0432.CCR-09-0636, 3471537, 20008848.
8. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100(15):8933-8938. 10.1073/pnas.1537685100, 166416, 12853564.
9. Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, Brandt BH, Dittmar T. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. J Pathol 2012, 227(2):234-244. 10.1002/path.3991, 22262199.
10. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196(1):17-25. 10.1002/path.1003, 11748637.
11. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200(3):290-297. 10.1002/path.1370, 12845624.
12. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004, 6(3):R246-R251. 10.1186/bcr783, 400680, 15084248.
13. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005, 11(6):2163-2168. 10.1158/1078-0432.CCR-04-1633, 15788662.
14. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008, 10(1):R2. 10.1186/bcr1843, 2374953, 18182100.
15. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol 2009, 175(5):1802-1809. 10.2353/ajpath.2009.090204, 2774046, 19808643.
16. Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res 2009, 11(4):R50. 10.1186/bcr2339, 2750111, 19624808.
17. Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K. Function of ERBB4 is determined by alternative splicing. Cell Cycle 2011, 10(16):2647-2657. 10.4161/cc.10.16.17194, 21811097.
18. Hollmén M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K. Proteolytic processing of ErbB4 in breast cancer. PLoS One 2012, 7(6):e39413. 10.1371/journal.pone.0039413, 3382207, 22761786.
19. Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2006, 17(1):67-79. 1345647, 16251361.
20. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, Aqeilan RI, Elenius K. Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci USA 2008, 105(11):4162-4167. 10.1073/pnas.0708333105, 2393780, 18334649.
21. Junttila TT, Laato M, Vahlberg T, Söderström KO, Visakorpi T, Isola J, Elenius K. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003, 9(14):5346-5357.
22. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005, 65(4):1384-1393. 10.1158/0008-5472.CAN-04-3150, 15735025.
23. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999, 59(20):5315-5322.
24. Hollmén M, Määttä JA, Bald L, Sliwkowski MX, Elenius K. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 2009, 28(10):1309-1319. 10.1038/onc.2008.481, 19151766.
25. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006, 66(12):6412-6420. 10.1158/0008-5472.CAN-05-2368, 16778220.
26. Junttila TT, Sundvall M, Määttä JA, Elenius K. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 2000, 10(7):304-310. Review, 10.1016/S1050-1738(01)00065-2, 11343971.
27. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13(2):259-268. 10.1007/s10911-008-9079-3, 18454307.
28. Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer 2010, 9:150. 10.1186/1476-4598-9-150, 2894764, 20550710.
29. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 2006, 66(16):7991-7998. 10.1158/0008-5472.CAN-05-4397, 16912174.
30. Das PM, Thor AD, Edgerton SM, Barry SK, Chen DF, Jones FE. Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells. Oncogene 2010, 29(37):5214-5219. 10.1038/onc.2010.271, 3007096, 20603612.
31. Fujiwara S, Ibusuki M, Yamamoto S, Yamamoto Y, Iwase H. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Breast Cancer 2012, [Epub ahead of print].
32. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001, 21(13):4265-4275. 10.1128/MCB.21.13.4265-4275.2001, 87087, 11390655.
33. Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS. The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell 2006, 17(9):4118-4129. 10.1091/mbc.E06-02-0101, 1556387, 16837552.
34. Hollmén M, Elenius K. Potential of ErbB4 antibodies for cancer therapy. Future Oncol 2010, 6(1):37-53. Review, 10.2217/fon.09.144, 20021208.
35. Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors. Cytometry A 2011, 79(9):684-693.